Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Clinical trial NCT06100237 · RECRUITING
Trial details
- NCT number
- NCT06100237
- Sponsor
- Carl Ola Landgren, MD, PhD
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-04
- Primary completion
- 2028-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.